Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial

Giuseppe Barbaro, Gabriella Di Lorenzo, Giancarlo Belloni, Luisella Ferrari, Aldo Paiano, Paolo Del Poggio, Donato Bacca, Luigi Fruttaldo, Franco Mongiò, Ruggiero Francavilla, Gaetano Scotto, Benvenuto Grisorio, Guido Calleri, Mauro Annese, Andrea Barelli, Piero Rocchetto, Giovanni Rizzo, Guido Gualandi, Italo Poltronieri, Giorgio Barbarini

Research output: Contribution to journalArticle

Abstract

PURPOSE: To assess the efficacy of interferon alpha-2b and ribavirin in combination in the treatment of patients with chronic hepatitis C who had either failed to respond to therapy with interferon alpha (nonresponders), or who had relapsed after interferon therapy (relapsers). SUBJECTS AND METHODS: Four hundred patients with chronic hepatitis C (200 nonresponders and 200 relapsers) were randomly assigned in equal numbers to receive either subcutaneous administration of recombinant interferon alpha-2b (3 million units three times per week) and ribavirin (1,000 to 1,200 mg/daily orally) or interferon alpha-2b alone (6 million units three times per week). Both ribavirin and interferon alpha-2b were given for 24 weeks. The patients were then followed for an additional 24 weeks. RESULTS: At the end of the treatment period, normalization of serum alanine aminotransferase levels and absence of hepatitis C virus RNA were seen in 21% of nonresponders and in 39% of relapsers who were treated with interferon alpha-2b and ribavirin, compared with 5% of nonresponders (P = 0.001) and 9% of relapsers treated with interferon alpha-2b alone (P

Original languageEnglish
Pages (from-to)112-118
Number of pages7
JournalAmerican Journal of Medicine
Volume107
Issue number2
DOIs
Publication statusPublished - Aug 1999

ASJC Scopus subject areas

  • Nursing(all)

Fingerprint Dive into the research topics of 'Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial'. Together they form a unique fingerprint.

  • Cite this

    Barbaro, G., Di Lorenzo, G., Belloni, G., Ferrari, L., Paiano, A., Del Poggio, P., Bacca, D., Fruttaldo, L., Mongiò, F., Francavilla, R., Scotto, G., Grisorio, B., Calleri, G., Annese, M., Barelli, A., Rocchetto, P., Rizzo, G., Gualandi, G., Poltronieri, I., & Barbarini, G. (1999). Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial. American Journal of Medicine, 107(2), 112-118. https://doi.org/10.1016/S0002-9343(99)00160-6